Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...
Nasdaq4d
Corbus Pharmaceuticals Presents Promising Phase 1 Dose-Escalation Study Findings for CRB-701 at ASCO GU 2025
Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...
Nasdaq4d
Corbus Presents CRB-701 Phase 1 Data With Promising Efficacy In Multiple Tumor Types At ASCO
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc.(CRBP), has reported promising data for CRB-701 or SYS6002, a next-generation Nectin-4 targeting antibody-drug conjugate or ADC, at the 2025 ...
Morningstar7d
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ...
Yahoo Finance8d
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
About CRB-701 CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2 ...